ClinConnect ClinConnect Logo
Search / Trial NCT05842161

South Africa Smoking Cessation and Engagement in HIV/TB Care Care

Launched by MASSACHUSETTS GENERAL HOSPITAL · Apr 24, 2023

Trial Information

Current as of August 29, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial, called the South Africa Smoking Cessation and Engagement in HIV/TB Care study, is focused on helping people who are living with HIV and/or tuberculosis (TB) quit smoking. Researchers are testing a new program called QUIT-AD, which combines existing methods to improve the chances of quitting smoking and achieving better health outcomes for those undergoing treatment for HIV and TB. The goal is to see if this program is easy to use, accepted by participants, and effective in helping them stop smoking, which can lead to better overall health.

To be eligible for this study, participants need to be at least 18 years old, willing to provide consent, and either living with HIV and on treatment or recently starting TB treatment. They should also smoke more than five cigarettes a day and be motivated to quit smoking. However, those who use other tobacco products, have certain untreated mental health issues, or are currently receiving other smoking cessation treatments cannot participate. If you join the study, you can expect support and resources to help you quit smoking while managing your health conditions. This trial could potentially improve health outcomes for many individuals in South Africa.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Aged 18 or older
  • 2. Willing and able to provide written informed consent
  • 3. Living with HIV, confirmed via medical record, and on antiretroviral therapy (ART) AND/OR within 1 month of initiating or reinitiating TB treatment; positive GeneXpert test or sputum culture
  • (5) Daily smoker operationalized as \> 5 cigarettes per day, (6) Motivation (\> 5/10) to quit smoking or \> 24 hour quit past yr
  • Exclusion Criteria:
  • 1. Habitual use of other tobacco products
  • 2. Current interfering untreated/unstable mental health condition (e.g., psychosis, bipolar dx)
  • 3. Current use of non-study pharmacotherapy for smoking cessation,
  • 4. Cognitive Behavioral Therapy for smoking cessation initiated within the past year,
  • 5. Diagnosed with extra-pulmonary or drug resistant (MDR or XDR) TB based upon chart review

About Massachusetts General Hospital

Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.

Locations

Rondebosch, , South Africa

Patients applied

0 patients applied

Trial Officials

Amelia Stanton, PhD

Principal Investigator

Boston University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported